戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 uggest a target for anti-HIV-1 chemotherapy, phosphodiesterase 4.
2  1 is mediated by PA-dependent modulation of phosphodiesterase 4.
3 lopment for COPD; they include inhibitors of phosphodiesterase 4.
4 bolic stability, and lacked activity against phosphodiesterase-4.
5 tion of phosphodiesterase 3B, in addition to phosphodiesterase 4D.
6      Human trabecular meshwork cells express phosphodiesterase 4, 5, and 7 gene family isoforms and e
7                Messenger RNA transcripts for phosphodiesterase 4, 5, and 7 isozymes were isolated in
8 s attributed to enhanced beta-arrestin 1 and phosphodiesterase 4 activities, while reduced desensitiz
9 P elevations in the PFC secondary to reduced phosphodiesterase 4 activity present in Disc1 deficiency
10 sine monophosphate levels through changes in phosphodiesterase-4D activity, and these effects are ind
11  trabecular meshwork cells only isozymes for phosphodiesterase 4 and 5 isozymes were detected.
12 ing the rolipram-sensitive cyclic nucleoside phosphodiesterase 4 and resulted in increased susceptibi
13 zing PA, which is an allosteric activator of phosphodiesterase 4 and the molecular target of rapamyci
14 UD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inh
15 atory mediators, that is, dimethyl fumarate, phosphodiesterase 4, and leukotriene B4 inhibitors in pe
16 t, one genomewide significant hit located in phosphodiesterase 4D, cAMP-specif (PDE4D) and 26 SNPs wi
17                                          The phosphodiesterase 4D, cAMP-specific (phosphodiesterase E
18                                              Phosphodiesterase 4 catalyzes the hydrolysis of cyclic A
19 ic adenosine monophosphate levels, increased phosphodiesterase-4 enzymatic activity, and phosphodiest
20 n and activates protein kinase A by reducing phosphodiesterase-4D expression, leading to increased BA
21                                Inhibition of phosphodiesterase 4 extends beta(2)AR-induced PKA activi
22 al infarction and stroke and PDE4D (encoding phosphodiesterase 4D) for ischemic stroke.
23 association between polymorphisms within the phosphodiesterase 4D gene (PDE4D) and ischemic stroke wa
24 ighting the therapeutic utility of targeting phosphodiesterase 4 in patients with AD.
25 ble small molecule that specifically targets phosphodiesterase-4, in the treatment of active psoriati
26    Crisaborole ointment 2% is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-
27                Importantly, treatment with a phosphodiesterase 4 inhibitor rescued the dedifferentiat
28                                          The phosphodiesterase 4 inhibitor roflumilast N-oxide (RNO)
29 we demonstrate that brief treatment with the phosphodiesterase 4 inhibitor rolipram ameliorates defic
30 ecific Food and Drug Administration-approved phosphodiesterase 4 inhibitor rolipram.
31 topical calcineurin inhibitors, or a topical phosphodiesterase 4 inhibitor to active lesion areas.
32 ial testing the combination of apremilast, a phosphodiesterase 4 inhibitor, and narrowband-ultraviole
33 Once-daily roflumilast cream, 0.3%, a potent phosphodiesterase 4 inhibitor, demonstrated efficacy and
34                     Roflumilast, a selective phosphodiesterase 4 inhibitor, has been shown to provide
35                                Apremilast, a phosphodiesterase 4 inhibitor, is commonly used for psor
36 /23, IL-17, and p19IL-23, as well as an oral phosphodiesterase 4 inhibitor.
37  occluded by PKA activator, and prevented by phosphodiesterase 4 inhibitor.
38 vanced small molecule apremilast, which is a phosphodiesterase 4 inhibitor.
39 of M. tuberculosis infected rabbits with the phosphodiesterase-4 inhibitor CC-3052 plus isoniazid sig
40                                          The phosphodiesterase-4 inhibitor roflumilast can improve lu
41 ions or treatment with the anti-inflammatory phosphodiesterase-4 inhibitor roflumilast prevents COPD-
42 ted after treatment before training with the phosphodiesterase-4 inhibitor rolipram (0.1 mg/kg, i.p.)
43 act of adjunctive immune modulation, using a phosphodiesterase-4 inhibitor that dampens the innate im
44                        Apremilast is an oral phosphodiesterase-4 inhibitor that modulates several inf
45    Restoring cAMP levels using the oral cAMP phosphodiesterase-4 inhibitor, apremilast, improves clin
46                               As a selective phosphodiesterase-4 inhibitor, rolipram also exhibits th
47  compounds, similar to thalidomide, were not phosphodiesterase 4 inhibitors and markedly stimulated T
48 ibitory drugs (SelCIDs) are a novel class of phosphodiesterase 4 inhibitors discovered during a thali
49 : one class of compounds, shown to be potent phosphodiesterase 4 inhibitors, inhibited TNF-alpha prod
50 ls, including macrolides, CXCR2 antagonists, phosphodiesterase 4 inhibitors, p38 mitogen-activating p
51 omethoxy-pyridinyl moiety features in potent phosphodiesterase 4D inhibitors that are considered to b
52                  The pharmacologic compounds phosphodiesterase-4 inhibitors (PDE4is) are small molecu
53 optimization of a series of 1,7-napthyridine phosphodiesterase-4 inhibitors is described.
54 pical agents such as tacrolimus ointment and phosphodiesterase-4 inhibitors offers new approaches dir
55 arinic antagonists, inhaled corticosteroids, phosphodiesterase-4 inhibitors, and macrolides, provide
56  drug candidates, including psychedelics and phosphodiesterase-4 inhibitors, are promising additions
57 transient receptor potential vanilloid), and phosphodiesterase-4-inhibitors (roflumilast, difamilast)
58                Further analysis reveals that phosphodiesterase 4 is the major family that shapes PKA
59 therapies that target AKT, protein kinase C, phosphodiesterase 4, mammalian target of rapamycin, hist
60 therefore explored if BPN14770, a prototypic phosphodiesterase-4D negative allosteric modulator (PDE4
61 acterized enzyme, nucleotide pyrophosphatase/phosphodiesterase-4 (NPP4), as a potent hydrolase of Ap3
62 flammatory treatments, such as inhibitors of phosphodiesterase 4 or nuclear factor kappaB, although t
63 so in development, and include inhibitors of phosphodiesterase-4, p38 mitogen-activated protein kinas
64 lidin ecarboxylate (1), a novel inhibitor of phosphodiesterase 4 (PDE 4), were investigated.
65 lular signal-regulated kinase (ERK)-mediated phosphodiesterase 4 (PDE4) activation and accompanied by
66 premilast), a novel potent and orally active phosphodiesterase 4 (PDE4) and tumor necrosis factor-alp
67 ry effects on phosphodiesterase 1 (PDE1) and phosphodiesterase 4 (PDE4) as well as for their inhibito
68 e naive CD4+ T cells, express high levels of phosphodiesterase 4 (PDE4) constitutively.
69                           Inhibitors of cAMP-phosphodiesterase 4 (PDE4) exert a number of promising t
70 ure leads to up-regulation of cAMP-degrading phosphodiesterase 4 (PDE4) expression, which compromises
71                                          The phosphodiesterase 4 (PDE4) family coordinates the degrad
72                 Members of the cAMP-specific phosphodiesterase 4 (PDE4) family, which contains >25 di
73     Inhibition of cyclic AMP (cAMP)-specific phosphodiesterase 4 (PDE4) has been proposed as a potent
74                                              Phosphodiesterase 4 (PDE4) has four isoforms (PDE4A-D) w
75                                              Phosphodiesterase 4 (PDE4) inhibition is associated with
76                                              Phosphodiesterase 4 (PDE4) inhibition restores the suppr
77 on or treatment with the clinically approved phosphodiesterase 4 (PDE4) inhibitor roflumilast.
78                         We now show that the phosphodiesterase 4 (PDE4) inhibitor rolipram (which rea
79 w (PLY), reduced it when co-applied with the phosphodiesterase 4 (PDE4) inhibitor rolipram.
80 loped to enhance the targeting efficiency of phosphodiesterase 4 (PDE4) inhibitor to the lungs for tr
81                       Crisaborole, a topical phosphodiesterase 4 (PDE4) inhibitor, became available i
82 wo phase III clinical studies found that the phosphodiesterase 4 (PDE4) inhibitor, roflumilast, reduc
83 time the therapeutic potential of a specific phosphodiesterase 4 (PDE4) inhibitor, rolipram, with ant
84              Development of orally available phosphodiesterase 4 (PDE4) inhibitors as anti-inflammato
85 We report in this paper the discovery of new phosphodiesterase 4 (PDE4) inhibitors for treatment of p
86                                         Oral phosphodiesterase 4 (PDE4) inhibitors, such as cilomilas
87                                              Phosphodiesterase 4 (PDE4) is a key cAMP-metabolizing en
88                                              Phosphodiesterase 4 (PDE4) is an essential contributor t
89                                              Phosphodiesterase 4 (PDE4) is the primary brain enzyme t
90     Here we find that transcripts related to phosphodiesterase 4 (PDE4) signaling are significantly e
91  is tightly controlled by negative regulator phosphodiesterase 4 (PDE4) that hydrolyzes cAMP.
92 sed drug screen and discovered inhibitors of phosphodiesterase 4 (PDE4) to be particularly effective
93                                Inhibition of phosphodiesterase 4 (PDE4) to increase endothelial cAMP
94 scaffolding protein DISC1 and cAMP-degrading phosphodiesterase 4 (PDE4) to regulate PDE4 activity.
95  We tested the hypothesis that inhibition of phosphodiesterase 4 (PDE4) with rolipram to increase vas
96 ed a dynamical model to study the effects of phosphodiesterase 4 (PDE4), a cAMP phosphodiesterase tha
97  we demonstrate that selective inhibition of phosphodiesterase 4 (PDE4), a family of enzymes that hyd
98 and increased activity and protein levels of phosphodiesterase 4 (PDE4), an enzyme that degrades cAMP
99 ed to a dual inhibition of p38alpha MAPK and phosphodiesterase 4 (PDE4), and the potential benefits a
100  and that activated Erk transiently inhibits phosphodiesterase 4 (PDE4), the enzyme that hydrolyzes c
101                                              Phosphodiesterase 4 (PDE4), the major cAMP-specific PDE
102                                              Phosphodiesterase 4 (PDE4), the primary cAMP-hydrolyzing
103 ia 1 (DISC1) and the cAMP-hydrolyzing enzyme phosphodiesterase 4 (PDE4).
104         We found that the phosphorylation of phosphodiesterase-4 (PDE4) by cyclin-dependent protein k
105                            Cyclic AMP (cAMP) phosphodiesterase-4 (PDE4) enzymes degrade cAMP and unde
106 ctivity by using (11)C-(R)-rolipram to image phosphodiesterase-4 (PDE4) in unmedicated MDD patients a
107 ctivity by using (11)C-(R)-rolipram to image phosphodiesterase-4 (PDE4) in unmedicated MDD patients a
108 8a was selected as a selective submicromolar phosphodiesterase-4 (PDE4) inhibitor associated with ant
109     Combining a beta(1)-AR antagonist with a phosphodiesterase-4 (PDE4) inhibitor during graded exerc
110 together with the specific cyclic AMP (cAMP) phosphodiesterase-4 (PDE4) inhibitor rolipram, but not t
111               Here we investigated whether 3 phosphodiesterase-4 (PDE4) inhibitors (rolipram, roflumi
112                                   Rationale: Phosphodiesterase-4 (PDE4) inhibitors have demonstrated
113                                              Phosphodiesterase-4 (PDE4) inhibitors have the potential
114                            Cyclic nucleotide phosphodiesterase-4 (PDE4) is a component of signaling p
115 ed with a profound up-regulation of specific phosphodiesterase-4 (PDE4) isoforms because of increased
116 clic adenosine monophosphate (cAMP)-specific phosphodiesterase-4 (PDE4) of the whitefly as an interac
117                                              Phosphodiesterase-4 (PDE4) plays an important role in me
118 bit neutrophilic inflammation; inhibitors of phosphodiesterase-4 (PDE4), p38 mitogen-activated protei
119                                              Phosphodiesterase-4 (PDE4), which metabolizes the second
120 for inhibitory activity toward cAMP-specific phosphodiesterase-4 (PDE4).
121 clic adenosine monophosphate (cAMP)-specific phosphodiesterase-4 (PDE4A-D).
122                            Osthole inhibited phosphodiesterase 4D (PDE4D) activity to amplify autocri
123                            Here we show that phosphodiesterase 4D (PDE4D) acts downstream of Neuropil
124 utative candidate genes for ischemic stroke: phosphodiesterase 4D (PDE4D) and 5-lipoxygenase activati
125 ive regulation of cAMP-specific 3',5'-cyclic phosphodiesterase 4D (PDE4D) and the regulatory subunit
126 e production without affecting cAMP-mediated phosphodiesterase 4D (PDE4D) gene expression, phospho-cA
127                           Here, we show that phosphodiesterase 4D (PDE4D) selectively impacts signali
128 in-induced phosphorylation and expression of phosphodiesterase 4D (PDE4D) through transactivation of
129 y regulates PKA-CREB signaling by repressing phosphodiesterase 4D (PDE4D) to prevent cAMP degradation
130 ion tomography (PET) radioligand for imaging phosphodiesterase 4D (PDE4D) would benefit drug discover
131  ATF4 binding region in the genomic locus of phosphodiesterase 4D (PDE4D), a gene implicated in psych
132   Mechanistically, SOC therapy downregulates phosphodiesterase 4D (PDE4D), a novel ER target gene in
133                  CC2D1A is known to regulate phosphodiesterase 4D (PDE4D), which regulates cyclic ade
134  proteosomal degradation of cAMP-hydrolyzing phosphodiesterase 4D (PDE4D).
135 oal of this study was to determine whether a phosphodiesterase-4D (PDE4D) allosteric inhibitor (BPN14
136                                              Phosphodiesterase-4D (PDE4D) has emerged as a significan
137  phosphodiesterase-4 enzymatic activity, and phosphodiesterase-4D (PDE4D) isoform-specific messenger
138 nhibition of the alpha(5) CT binding protein phosphodiesterase-4D (PDE4D), suggesting the involvement
139 t on NMDAR expression and function through a phosphodiesterase 4/PKA/CREB-dependent mechanism, which
140 vators of adenylate cyclase or inhibitors of phosphodiesterase 4) promoted degradation of short-lived
141 ically determined, and compounds that affect phosphodiesterase 4, protein kinase A, and cAMP producti
142 ocal protein kinase A-mediated activation of phosphodiesterase 4 resulting in hypophosphorylated phos
143 intact human cells, selective inhibitors for phosphodiesterase 4 (rolipram) and 5 (E4021) gene famili
144 ed region of recombinant human cAMP-specific phosphodiesterase 4 subtype A (rhPDE4A), we engineered t
145 e show that the genetic ablation of one cAMP-phosphodiesterase 4 subtype, PDE4B, is sufficient to pro
146 d were enhanced by rolipram, an inhibitor of phosphodiesterase 4, suggesting that the antiproliferati
147  containing PKA, PKC, calmodulin, and PDE4D (phosphodiesterase 4D) to the beta2-adrenergic receptor.
148 4D, which encodes cyclic AMP (cAMP)-specific phosphodiesterase 4D, were found to be heterozygous in t

 
Page Top